Agilent wins FDA backing to move more Keytruda-linked PD-L1 testing onto Dako Omnis
Find out how Agilent’s expanded PD-L1 test approval could change automated cancer diagnostics and oncology lab workflows.
AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
Imfinzi has FDA approval with BCG in early high-risk bladder cancer. The next test is adoption, recurrence data and real-world use.
Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.
Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?
Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.
How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN
Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.
Why Galderma’s acne gel approval could quietly reset the over the counter dermatology market
Acne care is moving from prescription desks to retail shelves. Galderma’s Differin Epiduo switch tests how far OTC dermatology can go.
What Kyowa Kirin’s Crysvita dosing change reveals about rare disease treatment individualisation
Rare disease dosing is becoming more personalised. Kyowa Kirin’s Crysvita update tests how far flexibility can improve adult XLH care.
FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.
Why Argenx’s broader Vyvgart label changes the treatment equation in generalized myasthenia gravis
Vyvgart now covers all adult gMG serotypes. Argenx gains a wider label, but payers and real-world durability remain the next test.
Citius Oncology raises $36.5m, but can Lymphir convert rare cancer approval into commercial traction?
Lymphir has funding and FDA approval. Citius Oncology now faces the harder test of turning rare cancer access into real adoption.